Bioventix (BVXP)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

1,860.00p
   
  • Change Today:
    -30.00p
  • 52 Week High: 3,400.00p
  • 52 Week Low: 1,700.00p
  • Currency: UK Pounds
  • Shares Issued: 5.22m
  • Volume: 3,711
  • Market Cap: £97.18m
  • Beta: 0.34

Latest Deals

Traded Action Notifier PriceAmountValue
25-Nov-25 Buy Bruce Hiscock 2,071.00p 150 £3,106.50
04-Nov-25 Buy Peter John Harrison 2,220.00p 875 £19,425.00
04-Nov-25 Buy Peter John Harrison 2,220.00p 875 £19,425.00
29-Oct-25 Buy Ian James Nicholson 1,865.00p 500 £9,325.00
27-Oct-25 Buy Bruce Hiscock 2,009.00p 119 £2,390.71

Largest Deals (365 days)

Traded Action Notifier PriceAmountValue
04-Nov-25 Buy Peter John Harrison 2,220.00p 875 £19,425.00
04-Nov-25 Buy Peter John Harrison 2,220.00p 875 £19,425.00
29-Oct-25 Buy Ian James Nicholson 1,865.00p 500 £9,325.00
25-Nov-25 Buy Bruce Hiscock 2,071.00p 150 £3,106.50
27-Oct-25 Buy Bruce Hiscock 2,009.00p 119 £2,390.71

Director Shareholdings

Notifier Holding Value*
Peter John Harrison 304,042 £5,655,181
Ian James Nicholson 13,500 £251,100
Bruce Hiscock 1,474 £27,416

Major Shareholders

Notifier** Holding Value*
Rathbones Investment Management Ltd 5,219,656 £97,085,602
Castlefield Fund Partners Limited 985,000 £18,321,000
SANFORD DELAND ASSET MANAGEMENT LTD 885,000 £16,461,000
Gresham House Asset Management Limited 627,782 £11,676,745
SANFORD DELAND ASSET MANAGEMENT LTD 619,500 £11,522,700
Miton Group plc 508,135 £9,451,311
The Diverse Income Trust plc 302,300 £5,622,780
Schroders plc 284,795 £5,297,187
Wasatch Advisors, Inc. 265,000 £4,929,000
Raymond James Wealth Management Limited 263,770 £4,906,122
Premier Miton Group plc 262,812 £4,888,303
Canaccord Genuity Group Inc 259,940 £4,834,884
Adrian Williams 253,372 £4,712,719

* Value is calculated by using the current share price multiplied by the amount held.
** Major Shareholders are individuals or institutions that own more than 3% of the company’s shares and have been reported in the annual accounts.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Bioventix Market Data

Currency UK Pounds
Share Price 1,860.00p
Change Today -30.00p
% Change -1.59 %
52 Week High 3,400.00p
52 Week Low 1,700.00p
Volume 3,711
Shares Issued 5.22m
Market Cap £97.18m
Beta 0.34

Bioventix Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
23.47% above the market average23.47% above the market average23.47% above the market average23.47% above the market average23.47% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Price Trend
67.33% below the market average67.33% below the market average67.33% below the market average67.33% below the market average67.33% below the market average
31.82% below the sector average31.82% below the sector average31.82% below the sector average31.82% below the sector average31.82% below the sector average
Income
60.89% above the market average60.89% above the market average60.89% above the market average60.89% above the market average60.89% above the market average
33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average
Growth
5.71% below the market average5.71% below the market average5.71% below the market average5.71% below the market average5.71% below the market average
65.52% below the sector average65.52% below the sector average65.52% below the sector average65.52% below the sector average65.52% below the sector average

Bioventix Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 06-Nov-25 10-Apr-25
Paid 21-Nov-25 25-Apr-25
Amount 80.00p 70.00p

Trades for 07-Jan-2026

Time Volume / Share Price
15:38 414 @ 1,865.00p
15:36 265 @ 1,890.00p
15:35 340 @ 1,852.00p
15:12 469 @ 1,861.00p
14:35 300 @ 1,895.00p

Bioventix Key Personnel

CEO Peter John Harrison
Chair Ian James Nicholson
CFO Bruce Hiscock

Top of Page